drugset / Trial / NCT00110916

Treatment for Patients With Osteoarthritis (OA) of the Knee

NCT00110916

Phase 2 Completed 165 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the clinical response in subjects with symptomatic OA of the knee following a single 50 mg anakinra, 150 mg anakinra or placebo intra-articular (IA) injection.

Timeline

Start
2004-06
Primary completion
2005-02
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 50 mg Other
Subject Anakinra Protein / enzyme biologic 150 mg Other

Indications